NVRO / Nevro Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36715 NEVRO CORP.* (Exact name of registrant as specified in its

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NEVRO CORP.

Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEVRO CORP. FIRST: The name of the corporation is Nevro Corp. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of the Corporation’s registered agent at such address is Corporation Service

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 NEVRO CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on April 14, 2025, pursuant to the provisions of Rule 12d2-2 (a).

SECOND AMENDED & RESTATED BYLAWS NEVRO CORP.

Exhibit 3.2 SECOND AMENDED & RESTATED BYLAWS OF NEVRO CORP. 1. OFFICES: 1.1. The Corporation may have an office or offices at such places as the Board of Directors may from time to time designate. 2. MEETING OF STOCKHOLDERS: 2.1. The annual meeting of stockholders for the election of directors shall be held at such time and date as may be fixed by the Board of Directors. 2.2. Special meetings of t

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

As filed with the Securities and Exchange Commission on April 3, 2025

S-8 POS As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 NEVRO CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Nevro Corp. Policy for Recovery of Erroneously Awarded Compensation.

Exhibit 97.1 NEVRO CORP. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of Nevro Corp. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 10. 1.Person

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Nevro Corp. Subsidiary Jurisdiction of Incorporation or Organization Nevro Medical Sarl Switzerland Nevro Medical Limited United Kingdom Nevro Medical Pty Ltd. Australia Nevro Germany GmbH Germany Nevro Medical, S.R.L. Costa Rica Nevro Medical CR, LLC United States Interventional Pain Technologies, Inc. d/b/a Vyrsa Technologies United States

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as

Nevro Corp. Non-Employee Director Compensation Program, as amended.

Exhibit 10.10 NEVRO CORP. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Nevro Corp. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board and effective January 1, 2025 (the “Effective Date”). The cash and equity c

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nevro Corp. Insider Trading Compliance Policy.

Exhibit 19.1 Nevro Corp. Amended and Restated Insider Trading Compliance Policy Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violating s

Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

Exhibit 99.1 Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results REDWOOD CITY, California – March 4, 2025 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. “We are pleased that adjusted EBITDA for the full-year

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee  Rate   Amount of  Filing Fee Fees to Be P

EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Nevro Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pr

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

EX-2 3 exhibit2.htm Exhibit 2 Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

Joint Filing Agreement

EX-1 2 exhibit1.htm Exhibit 1 Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the common stock of Nevro Corp. shall be filed on behalf of the undersigned. SHAY CAPITAL LLC By: Shay Capital Holdings LLC, its Manager By: /s/ Elan Foxman Name: Elan Foxman Title: Chief Financial Officer SHAY CAPITAL HOLDINGS LLC By: /s/ Elan Foxman Name: Ela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 NEVRO CORP. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 NEVRO CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

[Letter to Suppliers]

EX-99.3 Exhibit 99.3 [Letter to Suppliers] Valued Partner, Today Nevro Corp. and Globus Medical announced that we have entered into a definitive agreement for Globus Medical to acquire Nevro. Founded in 2003, Globus Medical is a leading and innovative musculoskeletal solutions company dedicated to solving unmet clinical needs and changing lives. Upon the expected closing of this transaction in the

[Email to All Employees]

Exhibit 99.2 [Email to All Employees] Team, I have some very exciting news to share with you – in a joint press release issued early this morning, Nevro Corp. and Globus Medical announced that Globus Medical has entered into a definitive agreement for Globus Medical to acquire Nevro. Founded in 2003, Globus Medical is a leading and innovative musculoskeletal solutions company dedicated to solving

[Letter to Customers]

EX-99.4 Exhibit 99.4 [Letter to Customers] February 6, 2025 Esteemed Colleague, Today Nevro Corp. and Globus Medical announced that we have entered into a definitive agreement for Globus Medical to acquire Nevro. Details of the transaction can be found in the joint press release included with this email. Founded in 2003, Globus Medical is a leading and innovative musculoskeletal solutions company

Voting and Support Agreement, dated as of February 6, 2025, by and among Nevro Corp., Globus Medical, Inc. and the other signatories thereto.

EX-10.1 Exhibit 10.1 Execution Version VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of February 6, 2025 (the “Agreement Date”), by and among Globus Medical, Inc., a Delaware corporation (“Parent”), Nevro Corp., a Delaware corporation (the “Company”), and the undersigned stockholders of the Company (each, a “Stockholder” and, collecti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 NEVRO CORP. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 NEVRO CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

EX-99.1 Exhibit 99.1 Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients AUDUBON, Pa. and REDWOOD CITY, Calif. – February 6, 2025 (GLOBE NEWSWIRE) – Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic p

[Letter to Physician Faculty]

Exhibit 99.5 [Letter to Physician Faculty] Esteemed Colleague, Today Nevro Corp. and Globus Medical announced that we have entered into a definitive agreement for Globus Medical to acquire Nevro. Details of the transaction can be found by clicking the button below: [Link to press release – PDF] In the coming weeks, we will schedule a faculty call for you to learn more about this transaction and wh

Agreement and Plan of Merger, dated as of February 6, 2025, by and among Globus Medical, Inc., Nevro Corp. and Palmer Merger Sub, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among GLOBUS MEDICAL, INC., PALMER MERGER SUB, INC. and NEVRO CORP. Dated as of February 6, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 5    1.1 Certain Definitions 5 1.2 Certain Interpretations. 18 ARTICLE II THE MERGER 20 2.1 The Merger 20 2.2 The Effective Time 20 2.3 The Closing 20 2.4 Effect of the Merger 20 2.5 Certifica

[Email to Sales Team]

Exhibit 99.6 [Email to Sales Team] Sales Team, As we shared a short time ago, Nevro Corp. and Globus Medical announced that we have entered into a definitive agreement for Globus Medical to acquire Nevro. Details on the transaction can be found in today’s press release included with this email. Founded in 2003, Globus Medical is a leading and innovative musculoskeletal solutions company dedicated

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024

Exhibit 99.1 Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, California – January 13, 2025 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic

NVRO / Nevro Corp. / Shay Capital LLC Passive Investment

SC 13G 1 e664057sc13g-nevro.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Nevro Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 64157F103 (CUSIP Number

©2024 Nevro Corp. All rights reserved. S000000 In addition to historical information, this presentation contains forward-looking statements reflecting the current beliefs and expectations of the company’s management, made pursuant to the safe harbor

©2024 Nevro Corp. All rights reserved. S000000 Third Quarter 2024 Earnings Conference Call November 11, 2024 Exhibit 99.2 ©2024 Nevro Corp. All rights reserved. S000000 In addition to historical information, this presentation contains forward-looking statements reflecting the current beliefs and expectations of the company’s management, made pursuant to the safe harbor provisions of the Private Se

Nevro Reports Third-Quarter 2024 Financial Results Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance

Exhibit 99.1 Nevro Reports Third-Quarter 2024 Financial Results Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, California – November 11, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financi

Nevro Corp. (NYSE: NVRO) Third-Quarter 2024 Earnings Call Transcript November 11, 2024

Exhibit 99.3 Nevro Corp. (NYSE: NVRO) Third-Quarter 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. Speakers Angeline C. McCabe Vice President, Investor Relations & Corporate Communications Kevin R. Thornal CEO & President Roderick H. MacLeod Senior Vice President & CFO Operator Good afternoon. My name is Christa, and I will be your conference operator today. At this time, I would like

NVRO / Nevro Corp. / Engaged Capital LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Nevro Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 64157F103 (CUSIP Number) GLENN W. WELLING ENGAGED

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numb

NVRO / Nevro Corp. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-nvro093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEVRO CORP (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 64157F103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant a

NVRO / Nevro Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Nevro Corp Title of Class of Securities: Common Stock CUSIP Number: 64157F103 Date of Event Which Requires Filing of this Statement: August 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1

NVRO / Nevro Corp. / ALGER ASSOCIATES INC - NEVRO CORP Passive Investment

Nevro Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nevro Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 64157F103 (CUSIP Number) August 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

Nevro Reports Second-Quarter 2024 Financial Results Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and

Exhibit 99.1 Nevro Reports Second-Quarter 2024 Financial Results Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, California – Au

Nevro Corp. Non-Employee Director Compensation Program, as amended

Exhibit 10.1 NEVRO CORP. Non-Employee DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Nevro Corp. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board and effective April 7, 2023 (the “Effective Date”). The cash and equity comp

, dated May 2, 2024, by and between Christopher C

DocuSign Envelope ID: 7DC9A5E6-B492-47BD-9303-CB88F226C992 Exhibit 10.2 Date: May 2, 2024 To: Chris Christoforou From: Kevin Thornal Subject: Promotion Dear Chris: Congratulations! I am pleased to confirm your promotion effective May 15th, 2024. Here are the details of the new role: New Title: Chief Operating Officer Base Salary: Your base salary will be $452,000.16 per year (Exempt - $18,833.34 s

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed  Maximum  Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par v

As filed with the Securities and Exchange Commission on August 6, 2024

As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as spe

NVRO / Nevro Corp. / ArrowMark Colorado Holdings LLC Passive Investment

SC 13G/A 1 arrowmark-nvro063024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nevro Corp. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 64157F103 (CUSIP Number) June 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 (State or other jurisdiction of incorporation) (Commission File Number) 1800 Bridge Parkway, Redwood City, CA 94065 (Address of principal executive offices) (Zip code) Kashif Rashid Senior Vice President,

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

Exhibit 1.01 to Form SD Nevro Corp. Conflict Minerals Report For the Period from January 1, 2023 to December 31, 2023 This Conflict Minerals Report is filed in accordance with Rule 13p-l and the Form SD, as required by the Securities Exchange Act of 1934, as amended, for the reporting period of January 1, 2023 to December 31, 2023 (“Reporting Period”). Nevro Corp. and Covered Product Overview Nevr

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2024 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (I

Nevro Reports First-Quarter 2024 Financial Results Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christo

Exhibit 99.1 Nevro Reports First-Quarter 2024 Financial Results Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, California – May 7, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as sp

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par val

Nevro Corp. Insider Trading Compliance Policy.

Exhibit 97.2 NEVRO CORP. INSIDER TRADING COMPLIANCE POLICY (Effective November 12, 2014, as amended on June 18, 2019 and Oct 1, 2020) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth Nevro Corp.’s (the “Company”) policies prohibiting insider trading; • Section III explains insider trading; • Section IV cons

Nevro Corp. Policy for Recovery of Erroneously Awarded Compensation.

Exhibit 97.1 Nevro Corp. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of Nevro Corp. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 10. 1. Perso

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its c

As filed with the Securities and Exchange Commission on February 23, 2024

As filed with the Securities and Exchange Commission on February 23, 2024 Registration No.

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Nevro Corp. Subsidiary Jurisdiction of Incorporation or Organization Nevro Medical Sarl Switzerland Nevro Medical Limited United Kingdom Nevro Medical Pty Ltd. Australia Nevro Germany GmbH Germany Nevro Medical, S.R.L. Costa Rica Interventional Pain Technologies, Inc. d/b/a Vyrsa Technologies United States

COOPERATION AGREEMENT

EX-99.1 2 ex991to13da109455055022124.htm COOPERATION AGREEMENT, DATED FEBRUARY 20, 2024 Exhibit 99.1 Execution version COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of February 20, 2024, by and among Nevro Corp., a Delaware corporation (the “Company”) and the persons set forth on Exhibit A hereto (collectively, the “Engaged Group” and, for clarity,

Cooperation Agreement, dated February 20, 2024, by and between Nevro Corp., Engaged Capital, LLC, Engaged Capital Holdings, LLC, Engaged Capital Flagship Master Fund, LP and Glenn W. Welling.

Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”) is made and entered into as of February 20, 2024, by and among Nevro Corp., a Delaware corporation (the “Company”) and the persons set forth on Exhibit A hereto (collectively, the “Engaged Group” and, for clarity, as applicable, including each member thereof acting individually). The Company and the Engaged Group are

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numb

NVRO / Nevro Corp. / Engaged Capital LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da10945505502212024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Nevro Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title

Nevro Enters Into Cooperation Agreement With Engaged Capital Appoints Kirt P. Karros to Board of Directors

Exhibit 99.1 Nevro Enters Into Cooperation Agreement With Engaged Capital Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif. – Feb. 21, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results Provides Full-Year and First-Quarter 2024 Guidance

Exhibit 99.1 Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, California – February 21, 2024 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results.

NVRO / Nevro Corp. / ALGER ASSOCIATES INC - NEVRO CORP Passive Investment

Nevro Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nevro Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 64157F103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

NVRO / Nevro Corp. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NVRO / Nevro Corp. / ArrowMark Colorado Holdings LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

NVRO / Nevro Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Nevro Corp Title of Class of Securities: Common Stock CUSIP Number: 64157F103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d

2,587,742 Shares Common Stock Offered by the Selling Securityholder

Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-276306 PROSPECTUS 2,587,742 Shares Common Stock Offered by the Selling Securityholder This prospectus relates to the proposed resale or other disposition of up to an aggregate of 2,587,742 shares of common stock, par value $0.001 per share (common stock), by the selling securityholder identified in this prospectus, which su

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 06, 2024 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results Fourth-Quarter 2023 Worldwide Revenue Exceeds Company’s Expectations Announces Restructuring to Support Company’s Long-Term Growth and Profitability

Exhibit 99.1 Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results Fourth-Quarter 2023 Worldwide Revenue Exceeds Company’s Expectations Announces Restructuring to Support Company’s Long-Term Growth and Profitability REDWOOD CITY, Calif. — January 9, 2024 — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for

Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065

Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 January 8, 2024 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: Nevro Corp. Registration Statement on Form S-3 Filed December 29, 2023 Registration No. 333-276306 Dear Mr. Augustin:

Filing Fee Table.

EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2)

As filed with the Securities and Exchange Commission on December 28, 2023

S-3 Table of Contents As filed with the Securities and Exchange Commission on December 28, 2023 Registration No.

NVRO / Nevro Corp / Engaged Capital LLC - THE SCHEDULE 13D Activist Investment

SC 13D 1 sc13d0945505512112023.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Nevro Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities)

JOINT FILING AGREEMENT

EX-99.1 2 ex991to13d0945505512112023.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.001 per

Nevro Announces Acquisition of Vyrsa™ Technologies Refinances with $200M Structured Debt Maturing in 2029

Exhibit 99.1 Nevro Announces Acquisition of Vyrsa™ Technologies Refinances with $200M Structured Debt Maturing in 2029 REDWOOD CITY, Calif. — November 30, 2023 — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has acquired Vyrsa Technologies (“Vyrsa”), a privately held med

Registration Rights Agreement, dated November 30, 2023, by and between Nevro Corp. and the Lenders listed thereto.

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 30, 2023, by and among Nevro Corp., a Delaware corporation (the “Company”), and Braidwell Transaction Holdings LLC – Series 4, a Delaware limited liability company (“Braidwell”). WHEREAS: A. In connection with the Credit Agreement and Guaranty, of even date herewith,

Form of Warrant to Purchase Common Stock of Nevro Corp.

Exhibit 4.1 Execution Version THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UND

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Credit Agreement and Guaranty, dated as of November 30, 2023, by and among Nevro Corp., as borrower, the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto, and Wilmington Trust, National Association, as administrative agent.

Exhibit 10.1 Execution Version CREDIT AGREEMENT AND GUARANTY dated as of November 30, 2023 by and among NEVRO CORP., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Subsidiary Guarantors, THE LENDERS FROM TIME TO TIME PARTIES HERETO, as the Lenders, and WILMINGTON TRUST, NATIONAL ASSOCIATION, as the Agent U.S. $200,000,000 TABLE OF CONTENTS Page Section 1 DEFINITI

Stock Purchase Agreement dated as of November 30, 2023, by and among Interventional Pain Technologies, Inc. d/b/a Vyrsa Technologies, Nevro Corp., the sellers of Interventional Pain Technologies, Inc. d/b/a Vyrsa Technologies and Project Andy Newco, LLC, as sellers representative.

Exhibit 2.1 Execution Version STOCK PURCHASE AGREEMENT by and among NEVRO CORP., INTERVENTIONAL PAIN TECHNOLOGIES, INC. D/B/A VYRSA TECHNOLOGIES, THE SELLERS LISTED ON ANNEX A ATTACHED HERETO, PROJECT ANDY NEWCO, LLC, AS SELLERS REPRESENTATIVE, and EACH OF PHILADELPHIA MEDICAL MANAGEMENT COMPANY LLC, CAMBER SPINE TECHNOLOGIES LLC, INSTITUTE FOR MUSCULOSKELETAL SCIENCE AND EDUCATION LTD. AND S1 SPI

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2023 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Rod MacLeod, CFO Nevro Corp. [email protected] Greg Chodaczek Gilmartin Group LLC [email protected] Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance REDWOOD CITY, California – November 1, 2023 – Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant a

Nevro Corp. Non-Employee Director Compensation Program, as amended.

Exhibit 10.1 NEVRO CORP. Non-Employee DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Nevro Corp. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board and effective April 7, 2023 (the “Effective Date”). The cash and equity comp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2023 NEVRO CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number

Amendment No. 1 to Change in Control Severance Agreement, dated as of April 19, 2023, by and between Kashif Rashid and the Company.

Exhibit 10.7 AMENDMENT NO. 1 TO AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE AGREEMENT This Amendment No. 1 (this “Amendment”) to the Amended and Restated Change in Control Severance Agreement (the “Agreement”), dated as of April 19, 2023, by and between Kashif Rashid (“Executive”) and Nevro Corp. (the “Company”) is entered into effective as of the latest date set forth by the signatures of th

Separation Agreement, dated June 30, 2023, by and between Niamh Pellegrini and the Company

Exhibit 10.9 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is entered into as of June 30, 2023 between Niamh Pellegrini (“Executive”) and Nevro Corp., a Delaware corporation (the “Company”), effective as of the eighth day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executive’s employment with the Company end

Change in Control Severance Agreement, dated June 20, 2023, between Greg Siller and the Company.

Exhibit 10.8 NEVRO CORP. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Greg Siller (“Executive”) and Nevro Corp. (the “Company”). This Agreement is effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). R E C I T A L S A. The Board of Directors of th

Amendment No. 1 to Change in Control Severance Agreement, dated as of April 19, 2023, by and between Niamh Pellegrini and the Company.

Exhibit 10.6 AMENDMENT NO. 1 TO CHANGE IN CONTROL SEVERANCE AGREEMENT This Amendment No. 1 (this “Amendment”) to the Change in Control Severance Agreement (the “Agreement”), dated as of April 19, 2023, by and between Niamh Pellegrini (“Executive”) and Nevro Corp. (the “Company”) is entered into effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective

Employment Agreement by and between Kevin Thornal and the Company, effective as of April 24, 2023.

Exhibit 10.3 NEVRO CORP. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Kevin Thornal (“Executive”) and Nevro Corp. (the “Company” and, together with Executive, the “Parties”), effective as of April 24, 2023 (the “Effective Date”). R E C I T A L S A. The Company desires to assure itself of the services of Executive by engaging Executive to

Offer Letter, dated as of June 1, 2023, by and between Greg Siller and the Company.

Exhibit 10.4 June 1, 2023 Dear Greg, On behalf of Nevro Corp. (the “Company” or “Nevro”), we are very pleased to offer you the position of Senior Vice President and Chief Commercial Officer, which will report to Chief Executive Officer. Your compensation described below is subject to final approval of the Compensation Committee (the “Compensation Committee”) of the Board of Directors of the Compan

Amendment No. 1 to Change in Control Severance Agreement, dated as of April 19, 2023, by and between Rod MacLeod and the Company.

Exhibit 10.5 AMENDMENT NO. 1 TO CHANGE IN CONTROL SEVERANCE AGREEMENT This Amendment No. 1 (this “Amendment”) to the Change in Control Severance Agreement (the “Agreement”), dated as of April 19, 2023, by and between Rod MacLeod (“Executive”) and Nevro Corp. (the “Company”) is entered into effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”

Offer Letter, dated as of April 17, 2023, by and between Kevin Thornal and the Company.

Exhibit 10.2 April 17, 2023 Dear Kevin, On behalf of Nevro Corp. (the “Company” or “Nevro”), we are very pleased to offer you the position of President and Chief Executive Officer, which will report to the Board of Directors. Your appointment as President and CEO and the associated compensation described below is subject to final approval of the Board of Directors of the Company (the “Board”). You

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as spe

Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Rod MacLeod, CFO Nevro Corp. 650-433-3247 | [email protected] Greg Chodaczek Gilmartin Group LLC 610-368-6505 | [email protected] Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Oppo

Amended and Restated Employment Agreement, by and between D. Keith Grossman and the Company, effective as of April 24, 2023.

Exhibit 10.1 NEVRO CORP. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into by and between D. Keith Grossman (“Executive”) and Nevro Corp. (the “Company” and, together with Executive, the “Parties”), effective as of April 24, 2023 (the “Effective Date”). R E C I T A L S A. The Company and Executive are parties to that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 (State or other jurisdiction of incorporation) (Commission File Number) 1800 Bridge Parkway, Redwood City, CA 94065 (Address of principal executive offices) (Zip code) Kashif Rashid General Counsel 650-43

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

Exhibit 1.01 to Form SD Nevro Corp. Conflict Minerals Report For the Period from January 1, 2022 to December 31, 2022 This Conflict Minerals Report is filed in accordance with Rule 13p-l and the Form SD, as required by the Securities Exchange Act of 1934, as amended, for the reporting period of January 1, 2022 to December 31, 2022 (“Reporting Period”). Nevro Corp. and Covered Product Overview Nevr

Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications and Investor Relations Officer 650-433-3247 | [email protected] Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance REDWOOD CITY, California – April 26, 2023 – Nevro Corp. (NYSE: NVRO), a global medical device com

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as sp

Nevro Corp. 2023 Employment Inducement Award Plan

EX-99.1 Exhibit 99.1 NEVRO CORP. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Nevro Corp. 2023 Employment Inducement Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Nevro Corp. (the “Company”) by linking the individual interests of Eligible Employees (as defined below) and those of the Company’s stock

Power of Attorney. Reference is made to the signature page to the Registration Statement.

As filed with the Securities and Exchange Commission on April 21, 2023 Registration No.

Filing Fee Table.

EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock,

Nevro Names Kevin Thornal as New Chief Executive Officer and President D. Keith Grossman to be Appointed as Executive Chairman Company Announces Preliminary, Unaudited Worldwide Revenue for First Quarter of 2023 of $96.3 Million and Reaffirms Full-Ye

EX-99 2 nvro-ex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications and Investor Relations Officer 650-433-3247 | [email protected] Nevro Names Kevin Thornal as New Chief Executive Officer and President D. Keith Grossman to be Appointed as Executive Chairman Company Announces Preliminary, Unaudited Worldwide Revenue for

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its c

As filed with the Securities and Exchange Commission on February 21, 2023

As filed with the Securities and Exchange Commission on February 21, 2023 Registration No.

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Nevro Corp. Subsidiary Jurisdiction of Incorporation or Organization Nevro Medical Sarl Switzerland Nevro Medical Limited United Kingdom Nevro Medical Pty Ltd. Australia Nevro Germany GmbH Germany Nevro Medical, S.R.L. Costa Rica

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par val

Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications and Investor Relations Officer 650-433-3247 | [email protected] Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance REDWOOD CITY, California – February 16, 2023 – Nevro Corp. (NYSE: NVRO), a global medical

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

NVRO / Nevro Corp / Jackson Square Partners, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236173d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Nevro Corp. (Name of Issuer) Common (Title of Class of Securities) 64157F103 (CUSIP Number) 12/31/

NVRO / Nevro Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Nevro Corp. Title of Class of Securities: Common Stock CUSIP Number: 64157F103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number

Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of

EX-99.1 2 nvro-ex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications and Investor Relations Officer 650-433-3247 | [email protected] Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance Company Announces 2023 Retirement Plans of D. Keith Grossman f

NVRO / Nevro Corp / Jackson Square Partners, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Nevro Corp. (Name of Issuer) Common (Title of Class of Securities) 64157F103 (CUSIP Number) 10/31/2022 (Date of Event Which Requires Filing

Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications & Investor Relations Officer 650-433-3247 | [email protected] Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy REDWOOD CITY, California, November 2, 2022 ? Nevro Corp. (NYSE: NVRO), del

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 07, 2022 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications & Investor Relations Officer 650-433-3247 | [email protected] Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance REDWOOD CITY, California, August 3, 2022 ? Nevro Corp. (NYSE: NVRO), delivering comprehensive, li

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as spe

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 NEVRO CORP (Exact name of Registrant as Specified in Its Charter) Delaware 001-36715 56-2568057 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications and Investor Relations Officer 650-433-3247 | [email protected] Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes REDWOOD CITY, California ? August

NVRO / Nevro Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Nevro Corp. Title of Class of Securities: Common Stock CUSIP Number: 64157F103 Date of Event Which Requires Filing of this Statement: June 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

Exhibit 1.01 to Form SD Nevro Corp. Conflict Minerals Report For the Period from January 1, 2021 to December 31, 2021 This Conflict Minerals Report is filed in accordance with Rule 13p-l and the Form SD, as required by the Securities Exchange Act of 1934, as amended, for the reporting period of January 1, 2021 to December 31, 2021 (“Reporting Period”). Nevro Corp. and Covered Product Overview Nevr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (IRS employer Identification No.) 1800 Bridge Parkway, Redwood City, CA 94065 (Address of principal executive offices) (Z

Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications & Investor Relations Officer 650-433-3247 | [email protected] Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance REDWOOD CITY, California, May 4, 2022 ? Nevro Corp. (NYSE: NVRO), delivering comprehensive, li

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as sp

Third Amendment to the Supply Agreement, effective as of November 1, 2021, by and between the Company and Greatbatch Ltd.

Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). THIRD AMENDMENT TO THE SUPPLY AGREEMENT This Third Amendment to the Supply Agreement (the ?Amendment?) is effective as of November 1, 2021, by and between Nevro Corp., having a mailing address of 1800 Bridge Parkway, Redwood City, CA 94065 (?Nevro?), and Greatbatch Ltd., having

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Nevro Corp. Subsidiary Jurisdiction of Incorporation or Organization Nevro Medical Sarl Switzerland Nevro Medical Limited United Kingdom Nevro Medical Pty Ltd. Australia Nevro Germany GmbH Germany Nevro Medical, S.R.L. Costa Rica

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numb

Nevro Corp. Non-Employee Director Compensation Program, as amended.

Exhibit 10.13 NEVRO CORP. Non-Employee DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Nevro Corp. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?), as amended by the Board and effective December 7, 2021 (the ?Effective Date?). The cash and equity

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its c

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Nevro Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par val

As filed with the Securities and Exchange Commission on February 23, 2022

As filed with the Securities and Exchange Commission on February 23, 2022 Registration No.

Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications & Investor Relations Officer 650-433-3247 | [email protected] Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance REDWOOD CITY, California, February 23, 2022 ? Nevro Corp. (NYSE: NVRO), delivering comprehensive, life

NVRO / Nevro Corp / Jackson Square Partners, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Nevro Corp. (Name of Issuer) Common (Title of Class of Securities) 64157F103 (CUSIP Number) 12/31/2021 (Date of Event Which Requires Filing

NVRO / Nevro Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Nevro Corp. Title of Class of Securities: Common Stock CUSIP Number: 64157F103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numbe

Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Company Expects to Exceed High End

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Chief Corp Communications and Investor Relations Officer 650-433-3247 | [email protected] Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Compa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant a

Nevro Corp. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data)

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance REDWOOD CITY, California, November 8, 2021 ? Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative,

NVRO / Nevro Corp / ALGER ASSOCIATES INC - NEVRO CORP. Passive Investment

Nevro Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nevro Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 64157F103 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number

Nevro Announces Director Appointment Healthcare Executive and Industry Veteran Sri Kosaraju Joins the Board

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Announces Director Appointment Healthcare Executive and Industry Veteran Sri Kosaraju Joins the Board REDWOOD CITY, California ? August 31, 2021 ? Nevro Corp. (NYSE: NVRO), a global medical device company that provi

Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance

EX-99.1 2 nvro-ex99154.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance REDWOOD CITY, California, August 4, 2021 – Nevro Corp. (NYSE: NVRO), a global medical devi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as spe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number)

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number)

Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) HFX™ for PDN Now the Only Spinal Cord Stimulation System Approved by FDA to Trea

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) HFX? for PDN Now the Only Spinal Cord Stimulation S

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (IRS employer Identification No.) 1800 Bridge Parkway, Redwood City, CA 94065 (Address of principal executive offices) (Z

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

EX-1.01 2 nvro-ex1017.htm EX-1.01 Exhibit 1.01 to Form SD Nevro Corp. Conflict Minerals Report For the Period from January 1, 2020 to December 31, 2020 This Conflict Minerals Report is filed in accordance with Rule 13p-l and the Form SD, as required by the Securities Exchange Act of 1934, as amended, for the reporting period of January 1, 2020 to December 31, 2020 (“Reporting Period”). Nevro Corp.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (I

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as sp

Nevro Corp. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data)

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Reports First Quarter 2021 Financial Results and Updates 2021 Guidance REDWOOD CITY, California, May 5, 2021 ? Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based s

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numb

Nevro Reports Fourth Quarter and Full Year 2020 Financial Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Reports Fourth Quarter and Full Year 2020 Financial Results REDWOOD CITY, California, February 24, 2021 ? Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based soluti

List of Subsidiaries.

Exhibit 21.1 List of Subsidiaries of Nevro Corp. Subsidiary Jurisdiction of Incorporation or Organization Nevro Medical Sarl Switzerland Nevro Medical Limited United Kingdom Nevro Medical Pty Ltd. Australia Nevro Germany GmbH Germany Nevro Medical, S.R.L. Costa Rica

- S-8

As filed with the Securities and Exchange Commission on February 24, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2020 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nevro Corp. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December 31, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nevro Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 64157F103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5) Under the Securities Exchange Act of 1934 Nevro Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUSIP Number) December 31,

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5) Under the Securities Exchange Act of 1934 Nevro Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 64157F103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedule is

JOINT FILING AGREEMENT

Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940

Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E.

SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Nevro, C

SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Nevro, Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 64157F103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of t

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Nevro Corp. Title of Class of Securities: Common Stock CUSIP Number: 64157F103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numbe

Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue Fourth Quarter 2020 Revenue of Approximately $109.7 Million Full-Year 2020 Revenue of Approximately $362.0 Million Company to Present at J.P. Morgan Healthcare Conferenc

Exhibit 99.1 FOR IMMEDIATE RELEASE Investors and Media: Julie Dewey, IRC Nevro Corp. Vice President, Investor Relations & Corp Communications 650-433-3247 | [email protected] Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue Fourth Quarter 2020 Revenue of Approximately $109.7 Million Full-Year 2020 Revenue of Approximately $362.0 Million Company to Present at J.P

Nevro Announces Director Appointment Industry Veteran Sue Siegel Joins the Board Founding Investor and Longtime Director Wilfred Jaeger Steps Down

Exhibit 99.1 Nevro Announces Director Appointment Industry Veteran Sue Siegel Joins the Board Founding Investor and Longtime Director Wilfred Jaeger Steps Down REDWOOD CITY, Calif., December 3, 2020 – Nevro Corp. (“Nevro”) (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that Susan E. Siegel has been a

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numb

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant a

Nevro Announces Third Quarter 2020 Financial Results -Worldwide revenues increase 8% - Nevro to submit PDN PMA Supplement to FDA in fourth quarter 2020

Exhibit 99.1 Nevro Announces Third Quarter 2020 Financial Results -Worldwide revenues increase 8% - Nevro to submit PDN PMA Supplement to FDA in fourth quarter 2020 REDWOOD CITY, Calif., November 5, 2020 – Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Numbe

Amendment to Supply Agreement, effective as of July 23, 2019, by and between the Company and Pro-Tech Design and Manufacturing, Inc.

Exhibit 10.4 Amendment to Supply Agreement This Amendment to Supply Agreement ("Amendment") is effective as of July 23, 2019 (the "Effective Date"), between Nevro Corp., a Delaware corporation (“Nevro”), and Pro-Tech Design and Manufacturing, Inc., a California corporation ("Pro-Tech"). The parties hereby agree to amend the Supply Agreement entered into between the parties effective July 23, 2014

Nevro Announces Second Quarter 2020 Financial Results

Exhibit 99.1 Nevro Announces Second Quarter 2020 Financial Results REDWOOD CITY, Calif., August 5, 2020 – Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the second quarter ended June 30, 2020. Worldwide revenue for the second quarter of 2020 was $56.4 milli

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as spe

Offer Letter, dated as of May 5, 2020, by and between Roderick H. MacLeod and the Company.

Exhibit 10.2 Nevro Corp • 1800 Bridge Parkway • Redwood City, CA 94065 USA • 650-251-0005 CONFIDENTIAL May 15, 2020 Dear Rod, On behalf of Nevro Corp. (the “Company” or “NEVRO”), we are very pleased to offer you the position of Chief Financial Officer. Your appointment is subject to approval of the Company’s Board of Directors and the compensation set forth below is subject to the approval of the

Second Amended and Restated Company Bonus Plan.

EX-10.1 2 nvro-ex10116.htm EX-10.1 Exhibit 10.1 Nevro Corp. Second Amended and Restated Company Bonus Plan 1. Purpose This Nevro Corp. Second Amended and Restated Company Bonus Plan (the “Plan”) is intended to provide an incentive for achievement of annual corporate and/or individual goals and to motivate eligible executives and employees of Nevro Corp. (the “Company”) and its subsidiaries toward

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number)

Change in Control Severance Agreement, dated as of June 15, 2020, by and between Roderick H. MacLeod and the Company.

Exhibit 10.3 NEVRO CORP. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Roderick MacLeod (“Executive”) and Nevro Corp. (the “Company”). This Agreement is effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). R E C I T A L S A.The Board of Directors o

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (

Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD.

EX-1.01 2 nvro-ex1016.htm EX-1.01 Exhibit 1.01 to Form SD Nevro Corp. Conflict Minerals Report For the Period from January 1, 2019 to December 31, 2019 This Conflict Minerals Report is filed in accordance with Rule 13p-l and the Form SD, as required by the Securities Exchange Act of 1934, as amended, for the reporting period of January 1, 2019 to December 31, 2019 (“Reporting Period”). Nevro Corp.

- SD

SD 1 nvro-sd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (IRS employer Identification No.) 1800 Bridge Parkway, Redwood City, CA 94065 (Address of principal e

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as sp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number) (I

Nevro Reports First Quarter 2020 Financial Results

Exhibit 99.1 Nevro Reports First Quarter 2020 Financial Results REDWOOD CITY, Calif., May 5, 2020 – Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the first quarter ended March 31, 2020. Worldwide revenue for the first quarter of 2020 was $87.5 million, a 6

Form of Performance Stock Award Agreement and Performance Stock Award Grant Notice under the 2014 Equity Incentive Award Plan.

Exhibit 10.1 Nevro Corp. 2014 EQUITY Incentive Award PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE Nevro Corp., a Delaware corporation, (the “Company”), pursuant to its 2014 Equity Incentive Award Plan, as amended from time to time (the “Plan”), granted to the holder listed below (the “Participant”) on the grant date set forth below (the “Grant Date”), an award of performance stock units (“Perfor

Assignment, Assumption and Amendment to Supply Agreement, effective as of December 31, 2019, by and between the Company, Greatbatch Ltd. and Centro de Construccion de Cardioestimuladores del Uruguay S.A.

Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT This Assignment, Assumption and Amendment Agreement (this “Agreement”) is effective as of December 31, 2019 (t

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number)

NVRO / Nevro Corp. DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

NVRO / Nevro Corp. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Letter Agreement, dated April 2, 2020, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Additional Call Option Transaction

EX-10.5 Exhibit 10.5 GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000 Opening Transaction April 2, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] A/C: To be provided From: Goldman Sachs & Co. LLC

Underwriting Agreement, by and between Nevro Corp. and Morgan Stanley & Co. LLC, dated April 1, 2020, related to the Notes.

EX-1.2 Exhibit 1.2 $165,000,000 Nevro Corp. 2.75% Convertible Senior Notes due 2025 Underwriting Agreement April 1, 2020 Morgan Stanley & Co. LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the sev

Letter Agreement, dated April 1, 2020, between Morgan Stanley & Co. International plc and Nevro Corp., regarding the Base Warrants.

EX-10.3 Exhibit 10.3 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 April 1, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] Re: Base Warrants The purpose of this letter agreem

Letter Agreement, dated April 1, 2020, between Morgan Stanley & Co. International plc and Nevro Corp., regarding the Base Call Option Transaction.

EX-10.4 Exhibit 10.4 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 April 1, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] Re: Base Call Option Transaction The purpose of thi

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 001-36715 56-2568057 (State or other jurisdiction of incorporation) (Commission File Number)

Underwriting Agreement, by and between Nevro Corp. and Morgan Stanley & Co. LLC, dated April 1, 2020, related to the Common Stock.

EX-1.1 2 d924665dex11.htm EX-1.1 Exhibit 1.1 Nevro Corp. 1,625,000 Shares of Common Stock Underwriting Agreement April 1, 2020 Morgan Stanley & Co. LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to t

Letter Agreement, dated April 1, 2020, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Base Warrants.

EX-10.1 Exhibit 10.1 GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212-902-1000 Opening Transaction Goldman Sachs & Co. LLC April 1, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] Re: Base Warrants The pur

Letter Agreement, dated April 2, 2020, between Morgan Stanley & Co. International plc and Nevro Corp., regarding the Additional Warrants.

EX-10.8 Exhibit 10.8 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 April 2, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] Re: Additional Warrants The purpose of this letter

Second Supplemental Indenture, dated April 6, 2020, by and between Nevro Corp. and Wilmington Trust, National Association, as Trustee.

EX-4.2 Exhibit 4.2 NEVRO CORP. AND WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of April 6, 2020 to Indenture dated as of June 13, 2016 2.75% Convertible Senior Notes due 2025 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions and References 2 Section 1.02 . References to Interest 11 Article 2 Issue, Description, Execution, Registrat

Letter Agreement, dated April 2, 2020, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Additional Warrants.

EX-10.6 Exhibit 10.6 GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212- 902-1000 Opening Transaction Goldman Sachs & Co. LLC April 2, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] Re: Additional Warrants

Letter Agreement, dated April 2, 2020, between Morgan Stanley & Co. International plc and Nevro Corp., regarding the Additional Call Option Transaction.

EX-10.7 Exhibit 10.7 Morgan Stanley & Co. International plc c/o Morgan Stanley & Co. LLC 1585 Broadway, 5th Floor New York, NY 10036 April 2, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] Re: Additional Call Option Transaction The purpose

Letter Agreement, dated April 1, 2020, between Goldman Sachs & Co. LLC and Nevro Corp., regarding the Base Call Option Transaction.

EX-10.2 Exhibit 10.2 GOLDMAN SACHS & CO. LLC | 200 WEST STREET | NEW YORK, NEW YORK 10282-2198 | TEL: 212- 902-1000 Opening Transaction April 1, 2020 To: Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 Attention: Andrew Galligan, cc: Kashif Rashid, General Counsel Telephone No.: 650-433-3205 Emails: [email protected]; [email protected] A/C: To be provided From: Goldman Sachs & Co. LL

Calculation of Registration Fee Title of each class of securities to be registered Amount to be registered Proposed maximum offering price per unit Proposed maximum aggregate offering price Amount of registration fee 2.75% Convertible Senior Notes du

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File No. 333-237482 Calculation of Registration Fee Title of each class of securities to be registered Amount to be registered Proposed maximum offering price per unit Proposed maximum aggregate offering price Amount of registration fee 2.75% Convertible Senior Notes due 2025 $189,750,000 (1)(2) 100% $189,750,000 (1)(2) $24,629.55 Common Sto

Nevro Corp. 2.75% Convertible Senior Notes due 2025

FWP Pricing Term Sheet Dated April 1, 2020 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No.

Calculation of Registration Fee Title of each class of securities to be registered Amount to be registered Amount of registration fee Common stock, par value $0.001 per share $156,975,000 $20,375.36

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File No. 333-237482 Calculation of Registration Fee Title of each class of securities to be registered Amount to be registered Amount of registration fee Common stock, par value $0.001 per share $156,975,000 $20,375.36 (1) Calculated pursuant to Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable

Subject to completion, dated April 1, 2020

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File No. 333-237482 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has become effective under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are n